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The efficiency of the treatments involving CNS disorders is commonly diminished by the
toxicity, reduced stability and lack of targeting of the administered neuroactive compounds. In
this study, we have successfully multifunctionalized CMCht/PAMAM dendrimer nanoparti-
cles by coupling the CD11b antibody and loading MP into the nanoparticles. The modification
of the new antibody-conjugated nanoparticles was confirmed by S-TEM observation and
1H NMR and FTIR spectroscopy. Cytotoxicity assays revealed that the conjugates did not affect
the viability of both primary cultures of glial
and microglial cells. Trace analyses of FITC-
labelled nanoparticles revealed that the uptake
of antibody-conjugated nanoparticles was con-
served in microglial cells but significantly
decreased in astrocytes and oligodendrocytes.
Thus, this study demonstrates that antibody
conjugation contributes to a modulation of
the internalization of these nanocarriers by
different cell types, whichmight be of relevance
for specific targeting of CNS cell populations.
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S. R. Cerqueira et al.1. Introduction and investigated for specific drug delivery purposesDrug delivery to the central nervous system (CNS) has been
a considerable challenge in biomedical research in the past
decades.[1,2] Neurological disorders such as Alzheimer’s
and Parkinson’s diseases, stroke, multiple sclerosis and
also neurotraumatic conditions, such as spinal cord injury
(SCI), are amongst the main debilitating disorders of our
times.[3] The unique environment and the complexity of
the mechanisms involved in these conditions, some of
which still poorly understood, have hindered the devel-
opment of new and efficient treatments. The systemic
administration of neuroactive molecules poses several
intrinsic issues, particularly its toxicity and reduced
stability in the organism.[4] Thus, there is an urgent
demand not only for more detailed knowledge of the
pathophysiology of CNS disorders, but also for more
specific and effective drug delivery strategies.[5,6] Another
major issue for drug delivery in the CNS is the presence of
biological barriers such as the blood–brain barrier (BBB)
and the blood-cerebrospinal fluid barrier (BCSFB) that can
obstruct the entry of therapeutic molecules to the nervous
tissues.[7,8] Nonetheless, one must distinguish diseases
that do not affect the BBB integrity from those which
compromise it.[9] In the first case, the major obstacle to an
effective cure of the disease is the BBB presence itself and
its characteristics. However, when this barrier has been
compromised, for instance, after neurotraumatic events,
the delivery of compounds is clearly eased.[10] In brain and
SCI physical damage occurs and the CNS barriers are
disrupted opening a ‘window of opportunity’ for the entry
of drugs that can limit the extent of following potential
secondary damage.[10,11] Still, efficient drug delivery to the
target cells remains a crucial task for the success of these
therapies, since most of these drugs are often highly
unspecific.[12]
The use of nanoparticle-based systems has gained
increasing interest in drug delivery with exciting pro-
spects.[13] These nanoscale materials present unique and
advantageous features in comparison to the classical drug
formulations, regarding its solubility, biodistribution,
release characteristics and immunogenicity.[14] In addi-
tion, nanoparticles are amenable to further modifications
that can provide higher functionalization degrees, namely
cell or tissue targeting.[13] Fundamentally, nanoparticle-
mediated selective drug delivery would offer a mean to
minimize delivery to unintended sites, allowing higher
doses of drug to be administered when reaching a precise
target site, thereby lowering peripheral cytoxicity. A
critical step in such a strategy is the internalization of
nanoparticles into specific cells, and a way to overcome it
would be the modification of the nanoparticle surface with
a ligand, that would be efficiently taken up by target
cells.[15,16] A vast range of nanoparticles is being developedMacromol. Biosci. 20
 2012 WILEY-VCH Verlag Gmbalthough from these only a small percentage is being
directed to CNS.[17,18]
A new surface engineered macromolecular carrier was
recently proposed to be used in CNS applications, showing
high internalization levels and no significant cytotoxicity
over neurons and glial cells.[19] Moreover, it has also shown
to be non-cytotoxic in vivo, revealing a wide biodistribution
after intravenous injections, being simultaneously able to
cross the BCSFB.[20] This system was firstly described as a
new surface engineered nanoparticle based on a poly-
amidoamine (PAMAM) dendrimer core grafted with the
natural polymer carboxymethylchitosan (CMCht).[21] The
sphere-like CMCht/PAMAM dendrimer nanoparticles were
proposed to be used as targeted drug delivery carriers for the
modulation of the cells’ behaviour by efficient intracellular
uptake upon its functionalization via: (i) drug incorpora-
tion; (ii) fluorescent labelling and (iii) ligand conjugation.[22]
Furthermore, an anti-inflammatory corticosteroid clini-
cally used in SCI related cases—methylprednisolone
(MP)—has already shown to be efficiently incorporated
and released from these nanoparticles, leading to impor-
tant alterations on the viability of primary cultures of
microglial cells.[23]
Therefore, following recent developments of these
previous works the aim of this study was to achieve a
higher functionalization level of the CMCht/PAMAM
dendrimer nanoparticles by conjugating to the latter a
targeting ligand, in order to determine a possible modula-
tion of their internalization behaviour in glial cells. From
the variety of potential ligands to nanoparticles surfaces,
monoclonal antibodies are attractive molecules due its high
specificity.[24] Therefore, the MP-loaded CMCht/PAMAM
dendrimer nanoparticles were conjugated to the CD11b
antibody which recognizes specific receptors on microglial
cells’ membranes. The multifunctional modification of the
CMCht/PAMAM dendrimer nanoparticles was confirmed
by Fourier transform infrared (FTIR) spectroscopy and
proton nuclear magnetic resonance (1H NMR). Then, we
have investigated its effects in the normal viability of glial
and microglial cells, in vitro. Finally, an assessment and
comparison of the two types of nanoparticles uptake in
mixed glial cultures was done following immunocyto-
chemistry and fluorescence microscopy observation.
Results revealed that conjugated nanoparticles were not
deleterious to both glial and microglial cells. Moreover, the
internalization profile of the new nanoparticles in a mixed
glial culture was indeed altered when compared to the
unmodified nanoparticles. This study demonstrates that by
following the above referred strategy it is possible to
modulate the internalization of MP-loaded CMCht/PAMAM
dendrimer nanoparticles by different glial cell populations,
rendering them with a cell targeted profile for future CNS
applications.12, 12, 591–597
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Scheme 1. Surface modification of MP-loaded CMCht/PAMAM dendrimer nanoparticles
with a fluorescent probe (FITC) and a targeting ligand (CD11b antibody).
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2.1. Dendrimer Nanoparticles
Preparation
2.1.1. Carboxymethylchitosan (CMCht)/
Polyamidoamine (PAMAM) Dendrimer
Nanoparticles Synthesis
Carboxymethylchitosan (CMCht)/PAMAM
dendrimer nanoparticles were produced as
previously reported by Oliveira et al.[21]Starburst PAMAM-carboxylic acid terminated dendrimer solution
(PAMAM-CT) (generation 1.5, 20% w/v) was purchased (Sigma,
Germany). The following reactions were carried out: (i) increase in
the PAMAM-CT generation; (ii) production of a PAMAM-methyl
ester terminated dendrimer; (iii) condensation reaction between
the methyl ester and amine groups of PAMAM and CMCht and
(iv) conversion of the non-reacting methyl ester groups into
carboxylic ones in the CMCht/PAMAM dendrimer nanoparticles.
Initially, the methanol was removed from the PAMAM-CT
dendrimers by evaporation under nitrogen gas. The remaining
compound was re-dissolved in ultra-pure water in a final
concentration of 10 mg mL1 and the pH was corrected to 6.5.
Then, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-
chloride (EDC, Fluka, Slovakia) was added under agitation for
30 min at room temperature. Ethylenediamine (EDA, Sigma,
Germany) was included at the same molar ratio and reacted for
4 h. The solution was subsequently dialysed against ultrapure
water in order to remove the exceeding EDC (cellulose tubing,
benzoylated for separating compounds with a molecular weight of
1 200, Sigma, Germany). The obtained amine terminated PAMAM
dendrimers (PAMAM-AT) were mixed with methanol (Sigma,
Germany) and methyl methacrylate (Fluka, Germany) and kept
under agitation in a water bath at 50 8C for 24 h. After methanol
removal under nitrogen gas, appropriate volumes of hydrochloric
acid (HCl, Panreac, Portugal) and trifluoroacetic acid (TFA, Sigma,
Germany) were added to the solution. Meanwhile, 1 g of CMCht was
dissolved in 50 mL of water. The PAMAM methyl ester terminated
dendrimers were dissolved in a 20:80 water/methanol solution and
the CMCht was added and kept under agitation for 72 h, after which
the CMCht/PAMAM dendrimer nanoparticles with carboxylic-
terminated groups were obtained.
2.1.2. Methylprednisolone Incorporation into the
CMCht/PAMAM Dendrimer Nanoparticles
Methylprednisolone (MP) was incorporated in the nanoparticles
by mixing an aqueous solution of CMCht/PAMAM dendrimer
nanoparticles with an ethanolic MP solution with a final
concentration of 5 104 M w/w and kept under vigorous agitation.
Saturated sodium carbonate solution (Na2CO3, Aldrich, Germany)
and acetone (Pronalab, Portugal) were then added to the mixture.
The resulting precipitates were collected by filtration and then
dispersed in ultrapure water. Extensive dialysis (cellulose tubing,
benzoylated for separating compounds with a molecular weight
of 1 200, Sigma, Germany) was performed during 48 h. Both
CMCht/PAMAM dendrimer nanoparticles and MP-loaded CMCht/
PAMAM dendrimer nanoparticles were obtained by freezing thewww.MaterialsViews.com
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Spain) the samples for approximately 7 d, until the solvents were
completely removed.
2.1.3. Fluorescent Labelling of MP-loaded CMCht/PAMAM
Dendrimer Nanoparticles
Fluorescein isothiocyanate (FITC, Sigma, Germany) labelled MP-
loaded CMCht/PAMAM dendrimer nanoparticles conjugates were
prepared by covalently bonding the amine group of CMCht and the
isothiocyanate group from FITC (Scheme 1). A 10 mg mL1 FITC
solution was prepared in dimethyl sulphoxide anhydrous (DMSO,
Riedel-de Haen, Germany) in the dark. Simultaneously, a
10 mg mL1 MP-loaded CMCht/PAMAM dendrimer nanoparticles
solution was set in carbonate-bicarbonate coupling buffer
(pH¼9.2). Afterwards, 50mL of the FITC/DMSO solution were
added per each mL of the MP-loaded CMCht/PAMAM dendrimer
nanoparticles buffered solution, under agitation. The resulting
solution was kept in the dark at 4 8C for 8 h. The FITC-labelled MP-
loaded CMCht/PAMAM dendrimer nanoparticles solution was
then dialysed (cellulose tubing, benzoylated for separating
compounds with a molecular weight of 1 200, Sigma, Germany)
for 48 h against ultrapure water in order to remove the FITC
molecules that did not react. Finally, the solution was frozen at –
80 8C and subsequently freeze-dried (Telstar-Cryodos-80, Spain)
until the solvents were completely removed.
2.1.4. CD11b Antibody Conjugation to CMCht/PAMAM
Dendrimer Nanoparticles
In order to conjugate anti-mouse CD11b antibody (BD Biosciences,
USA) to the dendrimer nanoparticles a crosslinking reaction was
performed (Scheme 1).[25] A 20 mg mL1 solution of nanoparticles
in phosphate buffer saline (PBS) was mixed with 1 mg mL1 EDC
(Fluka, Slovakia) and let react for 30 min. The remaining solution
was dialysed against ultrapure water for 24 h to remove the excess
EDC. Afterwards, the pH was corrected to 7.4 and 4 nmol of CD11b
antibody were added under agitation. One hour after CD11b
addition, the solution was frozen at 80 8C and subsequently
freeze-dried (Telstar-Cryodos-80, Spain).
2.1.5. Characterization of the CD11b Antibody Conjugated
Dendrimer Nanoparticles
The conjugation effectiveness was analysed by FTIR spectroscopy
and 1H NMR. The morphology of the new conjugated nanopar-
ticles was assessed by scanning-transmission electron micro-2, 12, 591–597
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S. R. Cerqueira et al.scopy (S-TEM). To obtain the FTIR spectra of the samples,
transparent potassium bromide (KBr, Pike Technologies, USA)
pellets were prepared containing the samples to be analysed. The
readings were run in an infrared spectroscope (IR Prestige-21,
Shimadzu, Japan). For the 1H NMR analyses the samples were
dispersed in deuterium oxide (D2O, Aldrich, Germany) at a final
concentration of 10 mg mL1. The one-dimensional 1H spectra
were acquired in a Varian Unity Plus spectrometer at 300 MHz and
20 8C. The morphology was then verified by S-TEM (Nova
NanoSEM 50 series, FEI Company, The Netherlands). For that
purpose, the lyophilized CD11b-antibody conjugated MP-loaded
CMCht/PAMAM dendrimer nanoparticles were dispersed in
ultrapure water to a final concentration of 1 mg mL1, stained
with 1% phosphotungstic acid and placed on copper grids for
further observation.
2.2. In vitro Cell Culture Studies
2.2.1. Isolation and Culturing of Rat Cortical Glial Cells
Neonatal rat cortices were isolated from P4 Wistar rat pups as
previously described.[26] Upon removal under aseptic conditions,
cortices were maintained in Hanks’ balanced salt solution
(HBSS, Gibco, USA) and mechanically dissected. Afterwards, the
cortical fragments were incubated in an enzymatic medium of
30 mg mL1 DNAse solution (Sigma, Germany) with 0.25% trypsin
(Sigma, Germany) in Ca2þ/Mg2þ free HBSS solution for 30 min at
37 8C. The trypsin reaction was blocked adding 40% foetal bovine
serum (FBS, Gibco, USA) and the resulting tissue was centrifuged at
800 rpm for 2 min and the cells were then plated out at a density of
4104 cells  cm2 on poly-L-lysine (Sigma, USA) coated coverslips.
Glial cells primary cultures were then maintained at 37 8C in a 5%
CO2 atmosphere, in Dulbecco’s modified Eagle medium (DMEM,
Gibco, USA) supplemented with 10% FBS and 1% antibiotic/
antimycotic for 7 d.
2.2.2. Establishment of Rat Cortical Microglial Cells
After the glial cells isolation procedure, these were plated out at a
density of 1106 cells  cm2 in polystyrene T75 flasks (Thermo
Scientific, USA) previously coated with poly-L-lysine (Sigma, USA).
The glial primary cultures were maintained at 37 8C in a 5% CO2
atmosphere in DMEM (Gibco, USA) supplemented with 10% FBS
and 1% antibiotic/antimycotic for 2 weeks, with periodical
medium renewal. After that, the flasks were agitated in an orbital
shaker at 240 rpm during 4 h. Following this, the medium
containing detached microglia cells was collected and the obtained
suspension was centrifuged at 1 200 rpm for 5 min. The pellet was
re-suspended in DMEM medium (Gibco, USA) supplemented with
10% FBS and 1% antibiotic/antimycotic and plated out at a density
of 4104 cells  cm2 on coverslips previously coated with poly-L-
lysine (Sigma, USA). Microglia cells primary cultures were then
maintained at 37 8C in a 5% CO2 atmosphere, in DMEM medium
(Gibco, USA) supplemented with 10% FBS and 1% antibiotic/
antimycotic for 4 d for further testing.
2.2.3. In vitro Cytotoxicity Assays
Unmodified and CD11b antibody-conjugated MP-loaded CMCht/
PAMAM dendrimer nanoparticles were evaluated regarding itsMacromol. Biosci. 20
 2012 WILEY-VCH Verlag Gmbinfluence in the primary cell cultures’ viability. For that purpose, two
concentrations of nanoparticles were tested: 200 and 400mg mL1
and the cultures were exposed to these conditions for a week.
For both glial and microglial cell cultures the cell viability was
verified after incubation of the cells at 37 8C for 3 h with (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulphophe-
nyl)-2H tetrazolium) (MTS, Promega, USA) in a 5:1 ratio. This
compound is bioreduced by active dehydrogenase enzymes into a
brown formazan product that is released to the medium. After
the incubation, the optical density of each sample was read in a
multiplate reader (Tecan Sunrise, Switzerland) at 490 nm.
2.2.4. Internalization Assessment by
Immunocytochemistry
After a week, the glial cultures were incubated with 200mg mL1
of CD11b antibody-conjugated and the unmodified FITC-labelled
MP-loaded CMCht/PAMAM dendrimer nanoparticles to assess
their internalization rates, 1 week after its addition. After this
time period, immunocytochemistry was performed. The cells were
washed in 0.1 M PBS and fixed in a 4% paraformaldehyde solution
for 30 min. For astrocytes recognition the wells were permeabilized
with Triton-X-100 (Merck, Germany) 0.3% for 5 min, following a
new wash in PBS 0.1 M. Afterwards, a 10% FCS solution in PBS
was added to the cells for 1 h and a new wash with PBS 0.1 M was
carried out. The next step consisted on the incubation with
the corresponding primary antibody diluted in 10% FCS in PBS.
The following antibodies were used: rabbit anti-rat glial fibrillary
protein (GFAP, Dako, Denmark, 1:500) for astrocytes recognition;
mouse anti-CD11b (BD Biosciences Pharmingen, USA, 1:100) in
microglial cells identification and mouse anti-O4 (R&D Systems,
1:50) for oligodendrocytes detection. After 1 h incubation, the cells
were washed in 0.5% FCS in PBS v/v for further 1 h incubation with
the secondary antibodies: Alexa Fluor 594 anti-mouse and Alexa
Fluor 568 anti-rabbit (both Molecular Probes, USA, 1:2000) were
incubated for 1 h. Negative controls were used performing the same
treatment but omitting the primary antibody addition. The cells
were then stained with 40,6-diamidine-2-phenyl indole (DAPI,
Thermo Scientific, USA, 1:2 000), for 5 min in the dark. The coverslips
were finally mounted for posterior observation under an Olympus
BX-61 Fluorescence Microscope (Olympus, Germany). The FITC-
labelled dendrimer nanoparticles internalization levels for each cell
population were determined according to Equation (1) (n¼3, 3
random fields/coverslip):12, 12, 5
H & CoI ¼ Pc
Tc
 100 (1)
the percentage of internalization, P the number of positiveI is c
cells for FITC-labelled dendrimer nanoparticles and Tc is the total
number of each cell type.
2.2.5. Statistical Analysis
Statistical evaluation was performed using the one-way analysis
of variance test followed by the Tukey’s post-test to assess the
statistical differences between groups in the viability and
internalization tests. Statistical significance was defined for
p< 0.05.91–597
. KGaA, Weinheim www.MaterialsViews.com
Figure 1. Characterization of the CD11b-conjugated CMCht/PAMAM dendrimer nano-
particles. (A) FTIR spectra of unmodified (NP) and CD11b-conjugated (NP CD11b) CMCht/
PAMAM dendrimer nanoparticles. Appearance of new peaks in the conjugated molecule
confirms the effective conjugation of the antibody to the dendrimer nanoparticles.
(B) 1H NMR spectra of unmodified (NP) and CD11b-conjugated (NP CD11b) CMCht/
PAMAM dendrimer nanoparticles. (C) STEM micrograph of CD11b-conjugated MP-loaded
CMCht/PAMAM dendrimer nanoparticles evidencing its spherical morphology.
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The partial failure in CNS disorders’
pharmacological treatments often
resides in the lack of targeting of the
administered therapeutic molecules.[4]
Even in conditions where the BBB has
been compromised and the delivery of
compounds is considerably facilitated, as
in SCI, efficient drug delivery to target
cells should be carefully considered. Due
to the massive inflammatory episodes
that follow these injuries, a cell-specific
drug delivery could be highly advanta-
geous in the control and modulation of
these deleterious events.[9] For instance,
MP clinical administration as an anti-
inflammatory drug aggravates a cascade
of side effects that could be minimized in
a targeted delivery strategy.[27] Following
previous works by our group focusing on
the development of a CNS targeted
dendrimer-based macromolecular car-
rier,[19,20,23] we aimed at further modify-ing the CMCht/PAMAM dendrimer nanoparticles to
achieve a higher functionalization degree.[28] For this
purpose, we tested a new surface modification by
conjugating a CD11b antibody to the MP-loaded CMCht/
PAMAM dendrimer nanoparticles. The latter had already
shown to be easily internalized by astrocytes, oligoden-
drocytes and microglial cells present in a mixed primary
culture. All these cell types revealed maximum internaliza-
tion levels 24 h after exposure to these nanoparticles, being
microglial cells the ones with faster uptakes.[23] If we intend
to target the delivery of the drug to microglial cells, for
instance, minimum amounts should reach the other cell
types in order to maximize the desired drug actions while
minimizing possible side effects. Therefore, it was inves-
tigated whether this generalized internalization intake
would be affected by the presence of CD11b antibody,
which is specific for microglial cell recognition. The CD11b
antibody was chosen to facilitate the permeation of the
nanoparticles through the microglial cells membrane by
specifically interacting with an integrin chain expressed
only in this type of cells. In this way, the nanoparticles could
still be targeted to microglial cells, but its entrance in the
other cell types would be compromised.
In the present study, it was initially investigated the
conjugation of the CD11b antibody to the CMCht/PAMAM
dendrimer nanoparticles. FTIR spectra of the unmodified
and antibody-conjugated CMCht/PAMAM dendrimer
nanoparticles are represented in Figure 1A. From
Figure 1, it is visible that the antibody-conjugated
nanoparticles disclose an altered FTIR spectrum as com-www.MaterialsViews.com
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amino acid peak and the 1 120 cm1 NHþ3 vibration appear
after modification of the nanoparticles in the antibody-
conjugated nanoparticles spectrum. Consequently, the
comparative FTIR spectra analysis of the unmodified and
CD11b conjugated dendrimer nanoparticles seems to
suggest that the antibody was, in fact, successfully
conjugated to the nanoparticles. Also the 1H NMR spectra
of CD11b antibody-conjugated and unmodified CMCht/
PAMAM dendrimer nanoparticles (Figure 1B) revealed new
proton signals which indicate that the conjugation actually
occurred. Some characteristic peaks of the CMCht/PAMAM
dendrimer nanoparticles are maintained in both spectra,
such as the 2.17 ppm CH2 protons from the PAMAM
dendrimer and the 4.07 ppm CH2COO
– protons from CMCht.
Also new signals were observed at 1.26 ppm and 2.71 ppm
which are attributed to new COCH3 and NCH3 protons from
the newly formed bonds. These new signals strongly
suggest that the conjugation of CD11b antibody to the
nanoparticles actually occurred. Additionally, STEM ana-
lysis (Figure 1C) also confirmed the spheric morphology of
these nanoparticles.
Regarding the biological assays, both the glial and
microglial cell cultures were incubated with two different
concentrations of the CD11b-conjugated and the unmodi-
fied MP-loaded CMCht/PAMAM dendrimer nanoparticles.
The metabolic activity was then quantified by means of
performing an MTS assay. In all the tested conditions no
negative effect in the normal cell activity was observed
(Figure 2). Both cell populations reduced detectable2, 12, 591–597
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Figure 2. Metabolic activity measured with MTS assay of glial and microglial cultures
after exposure to the unmodified (NPmp-FITC) and CD11b conjugated (CD11b-NPmp-
FITC) CMCht/PAMAM dendrimer nanoparticles. Values are shown as
mean SD (n¼ 3), p<0.05.
Figure 3. Nanoparticles cell uptake by primary glial cell cultures.
(A) The presence of the CD11b antibody in the nanoparticles
induced a significant decrease in the number of astrocytes and
oligodendrocytes internalizing nanoparticles 7 d after exposure.
(n¼ 3; 5 fields/coverslip; mean SD) p<0.01; p<0.001.
(B) Fluorescence microscopy observation of a mixed primary glial
culture after immunostaining with anti-GFAP primary antibody
for astrocytes labelling and anti-O4 primary antibody for oligo-
dendrocytes recognition. Nuclei were counterstained with DAPI.
The cells were exposed to unmodified (left) and CD11b-conjugated
MP-loaded CMCht/PAMAM dendrimer nanoparticles (right)
during 7 d.
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S. R. Cerqueira et al.amounts of MTS in similar ways to those of control cultures,
showing normal cell viability and metabolism. Only a
slight, but significant, increase in the metabolic activity of
glial cells after 200mg addition of CD11b-conjugated MP-
loaded CMCht/PAMAM dendrimer nanoparticles was
observed. These data suggest that there is no cytotoxicity
derived from the exposure of these cells to the multi-
functionalized nanoparticles.
The internalization of the nanoparticles by each cell type
in the mixed primary culture of glial cells was then further
investigated. To allow both a qualitative and a quantitative
evaluation, cells were immunostained for observation and
the number of cells containing fluorescently labelled
internalized nanoparticles was determined. A previous
study has shown that microglial cells presented maximum
MP-loaded CMCht/PAMAM dendrimer nanoparticles inter-
nalization levels, with all cells evidencing nanoparticles
within its cytoplasmic compartment 24 h after nanopar-
ticles addition.[23] Moreover, astrocytes also reached high
internalization levels around 90% followed by oligoden-
drocytes, which presented a slightly lower percentage of
nanoparticles internalizing cells (around 80%). As observed
in Figure 3, the CD11b conjugation to the MP-loaded
CMCht/PAMAM dendrimer nanoparticles did not alter the
percentage of microglial cells internalizing the nanoparti-
cles as compared to cultures exposed to MP-loaded CMCht/
PAMAM dendrimer nanoparticles. Importantly, however,
this was not true for the other glial cell types. Regarding
astrocytes, a drastic and significant decrease in the anti-
body-conjugated nanoparticles uptake was observed
(around 50%), as seen in Figure 3. Similar to what it was
observed in astrocytes, oligodendrocytes also revealed a
significant decrease regarding the CD11b-conjugated MP-
loaded CMCht/PAMAM dendrimer nanoparticles uptake.
Again, the number of oligodendrocytes internalizing the
modified nanoparticles was drastically reduced to 40%
when compared to the unmodified nanoparticles condition.
The endocytosis pathway is believed to be the major route
for dendrimer nanoparticles internalization,[21,29] and it
was already shown that surface modifications modulateMacromol. Biosci. 2012, 12, 591–597
 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinhethis mechanism.[30] Thus, our strategy to
modify the nanoparticles with an anti-
body that is efficiently taken up by
microglial cells via receptor-mediated
endocytosis seems to be advantageous
in diminishing the non-specific uptake
modulation by other cell types, such as
astrocytes and oligodendrocytes. The
yield of nanoparticles internalization by
microglial cells did not improve, since
maximum percentage figures wereim www.MaterialsViews.com
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www.mbs-journal.dealready being reached. However, the receptor-mediated
endocytosis facilitation to microglial cells, due to the
interaction of CD11b antibody-conjugated nanoparticles,
indeed contributed to the improvement of their intracel-
lular uptake and conferred a targeted profile to the system,
drastically reducing the uptake by astrocytes and oligoden-
drocytes.
Thus, we demonstrate that the CD11b antibody-
conjugated MP-loaded CMCht/PAMAM dendrimer nano-
particles can be beneficial when envisioning the develop-
ment of targeted therapies aimed at applications in CNS
disorders, namely by carrying anti-inflammatory drugs
such as MP to inflammation mediator cells.4. Conclusion
Within the present study it was possible to describe for the
first time the successful functionalization of MP-loaded
CMCht/PAMAM dendrimer nanoparticles with a microglia-
specific antibody, acting as a targeting ligand. The new
sphere-like CD11b antibody-conjugated nanoparticles
revealed no cytotoxicity when added to glial and microglial
primary cell cultures. Furthermore, a novel nanoparticle
uptake profile by astrocytes and oligodendrocytes was
achieved with the new modified nanoparticles. These cells
significantly reduced the levels of CD11b antibody-con-
jugated nanoparticles internalization, while maintaining
maximum uptake by microglial cells. Further studies will
focus on the potential selective anti-inflammatory action of
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